1. A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma. (December 2016) Authors: Langenberg, M.H.; Gluck, L.; Weger, V.; Frank, R.; Eskens, F.; Blay, J.Y.; Soria, J.C.; Chawla, S.; Gounder, M.; Wagner, A.; Zhang, Y.; Kambuj, P.; Loberg, R.; Henary, H. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗